Search Results 791-800 of 14837 for anti-TNF drugs

  1. Bismuth Subsalicylate, Metronidazole, And Tetracycline (Oral Route) Precautions - Mayo Clinic

    Children or teenagers who have or who are recovering from chickenpox or influenza should not use this medicines unless directed by the child's doctor. If nausea ...

  2. Efavirenz, Lamivudine, And Tenofovir (Oral Route) Description and Brand Names - Mayo Clinic

    Description and Brand Names. Drug information provided by: Merative, Micromedex®. US Brand Name. Symfi; Symfi Lo. Descriptions.

  3. Topotecan (Intravenous Route) Description and Brand Names - Mayo Clinic

    Topotecan belongs to the group of medicines called antineoplastics. It interferes with the growth of cancer cells, which are eventually destroyed.

  4. Tuberculin (Intradermal Route) Side Effects - Mayo Clinic

    Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...

  5. Bictegravir, Emtricitabine, And Tenofovir Alafenamide (Oral Route) Precautions - Mayo Clinic

    Using these medicines together may cause serious or life-threatening side effects. Tell your doctor if you are pregnant or become pregnant during treatment with ...

  6. Spiramycin (Oral Route, Injection Route, Rectal Route) Description and Brand Names - Mayo Clinic

    Description and Brand Names. Drug information provided by: Merative, Micromedex®. Descriptions. Spiramycin is used to treat many kinds of infections.

  7. Peginterferon Alfa-2a (Subcutaneous Route) Before Using - Mayo Clinic

    Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

  8. Tildrakizumab-Asmn (Subcutaneous Route) Side Effects - Mayo Clinic

    Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...

  9. Development of PARP Inhibitors and DDR Modifiers To Treat Ovarian Cancer - Anticancer Drug Action Laboratory - Mayo Clinic Research

    Dr. Kaufmann and his team in the Anticancer Drug Action Lab at Mayo Clinic are studying the susceptibility of HR-deficient cancer cells to PARP inhibitors ...

  10. Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer - Mayo Clinic

    ... TNF] agents) within 4 weeks prior to cycle 1, day ... drugs); replacement therapy ... A stable regimen of highly active anti-retroviral therapy (HAART) ...